Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TX103 CAR-T Cells in Advanced Solid Tumors
NCT07231081Phase 1Suspended
- Sponsor
- Tcelltech GmbH
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of tx-103 in solid tumor (3 cohorts), sponsored by Tcelltech GmbH. Primary endpoints: Incidence and severity of adverse events at 1 year, Incidence of Dose Limiting Toxicity at 28 days and 1 more. Started Oct 2025; status: suspended.
02
Drugs
tx-103
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07231081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231081.